Unknown

Dataset Information

0

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.


ABSTRACT: The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma LDL-cholesterol (LDL-C) levels can be controlled. Initially, the therapeutic approaches to reduce circulating levels of PCSK9 were focused on the use of monoclonal antibodies. To that effect, evolocumab and alirocumab, two human monoclonal antibodies directed against PCSK9, given on a background of statin therapy, have been shown to markedly decrease LDL-C levels and significantly reduce cardiovascular risk. The small interfering RNA (siRNA) molecules have been used recently to target the hepatic production of PCSK9. siRNA interferes with the expression of specific genes with complementary nucleotide sequences by affecting the degradation of mRNA post-transcription, thus preventing translation. Inclisiran is a long-acting, synthetic siRNA directed against PCSK9 and it has been shown to significantly decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels. This review aims to present and discuss the current clinical and scientific evidence pertaining to inclisiran, which is a new promising agent in the management of hypercholesterolemia.

SUBMITTER: Kosmas CE 

PROVIDER: S-EPMC6163360 | biostudies-other | 2018 Jul

REPOSITORIES: biostudies-other

altmetric image

Publications

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.

Kosmas Constantine E CE   Muñoz Estrella Alba A   Sourlas Andreas A   Silverio Delia D   Hilario Elizabeth E   Montan Peter D PD   Guzman Eliscer E  

Diseases (Basel, Switzerland) 20180713 3


The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma LDL-cholesterol (LDL-C) levels can be controlled. Initially, the therapeutic approaches to reduce circulating levels of PCSK9 were focused on the use of monoclonal antibodies. To that effect, evolocumab and alirocumab, two human monoclonal antibodie  ...[more]

Similar Datasets

| S-EPMC4976866 | biostudies-literature
| S-EPMC10016360 | biostudies-literature
| S-EPMC6225138 | biostudies-literature
| S-EPMC6777550 | biostudies-literature
| S-EPMC8775589 | biostudies-literature
| S-EPMC10711515 | biostudies-literature
| S-EPMC5014894 | biostudies-literature
| S-EPMC10571651 | biostudies-literature
| S-EPMC5564795 | biostudies-other
| S-EPMC5019477 | biostudies-literature